Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week announced that the US Food and Drug Administration (FDA) granted ...
Geleen, June 9, 2026Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today ...
CAR T therapies have transformed treatment options for some blood cancers. They have also exposed one of cell therapy's ...
FDA cleared the Harmony-HHT Phase 1/2 study design, enabling Atavistik Bio to leverage existing clinical data with ATV-1601 and advance directly ...
FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal ...
Dr Arun Swaminathan tells Salong Debbarma how COYA 302’s FDA fast track status is shaping Coya’s next steps, from ...
MNV-201, a mitochondrial cell therapy, received FDA fast track designation for myelodysplastic syndrome, highlighting its potential to address mitochondrial dysfunction in this serious blood disorder.
TARPON SPRINGS, Fla., August 26, 2025-- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...
FDA fast track designation targets advanced HCC with FGF19 overexpression after ICI and mTKI exposure, reflecting an unmet-need population with limited post-progression systemic options. Phase 1 ...
The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by ...
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results